Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition
Qi Wang, Juan Liu, Yinan Hu, Ting Pan, Yongjian Xu, Jun Yu, Weining Xiong, Qing Zhou, Yi Wang
Abstract
Accordingly, these data indicate that Srpx2 plays an essential role in the pathogenesis of pulmonary fibrosis and suggests the strategy aiming at silencing Srpx2 could be a promising therapeutic approach against pulmonary fibrosis in clinical settings.
Topics & Concepts
MyofibroblastPulmonary fibrosisIdiopathic pulmonary fibrosisCancer researchFibroblastEpithelial–mesenchymal transitionExtracellular matrixGene silencingFibrosisSMADLungMedicineDownregulation and upregulationPathogenesisTransforming growth factorParenchymaPathologyBiologyCell biologyCell cultureInternal medicineGeneticsBiochemistryGeneInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisMedical Imaging and Pathology StudiesNeonatal Respiratory Health Research